|Dr. Helen I. Torley||Pres, CEO & Director||1,57M||N/A||1963|
|Ms. Laurie D. Stelzer||Sr. VP & CFO||802,9k||N/A||1968|
|Mr. Harry J. Leonhardt||Sr. VP, Gen. Counsel & Corp. Sec.||757,57k||N/A||1957|
|Dr. Dimitrios Chondros||Chief Medical Officer & Sr. VP||937,77k||N/A||1965|
|Mr. Benjamin J. Hickey||Sr. VP & Chief Commercial Officer||828,89k||N/A||1975|
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. The company was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics, Inc.s ISS Governance QualityScore, Stand 25. Juni 2019, lautet 3. Die grundlegenden Scores sind Audit: 2, Vorstand: 1, Shareholderrechte: 5, Kompensation: 5.